You are here » Home » Companies » Company Overview » Anuh Pharma Ltd

Anuh Pharma Ltd.

BSE: 506260 Sector: Health care
NSE: N.A. ISIN Code: INE489G01022
BSE LIVE 12:53 | 08 Dec 210.95 1.10
(0.52%)
OPEN

209.50

HIGH

211.95

LOW

208.00

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 209.50
PREVIOUS CLOSE 209.85
VOLUME 898
52-Week high 344.00
52-Week low 159.00
P/E 27.65
Mkt Cap.(Rs cr) 528.64
Buy Price 209.00
Buy Qty 104.00
Sell Price 211.00
Sell Qty 178.00
OPEN 209.50
CLOSE 209.85
VOLUME 898
52-Week high 344.00
52-Week low 159.00
P/E 27.65
Mkt Cap.(Rs cr) 528.64
Buy Price 209.00
Buy Qty 104.00
Sell Price 211.00
Sell Qty 178.00

Anuh Pharma Ltd. (ANUHPHARMA) - Chairman Speech

Company chairman speech

ANUH PHARMA LIMITED ANNUAL REPORT 2011-2012 CHAIRMAN'S REPORT Dear Shareholders, It is a pleasure to share my thoughts with you as we present our 52nd Annual Report for Anuh Pharma Limited. Anuh Pharma Limited has been an integral part of the SK Group. This year, the SK Group completes 80 years of service to the pharmaceutical industry. The group was founded way back in 1932, and has evolved over these eight decades as a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical/formulations. Anuh Pharma Limited has delivered yet another outstanding performance for the year 2011-12. What makes this performance especially outstanding is the fact that it was achieved at a time when the macro-environment was difficult due to overall uncertainty in Eurozone, modest recovery in the US and slowing growth in India. The global pharmaceutical industry has been growing at the rate of 7%. While R & D and innovations within the industry are still majorly dominated by MNCs based in the western world, the manufacturing focus has been shifting to Asian giants-China and India. China continues to remain the biggest manufacturing centre followed by Italy and India, and it is estimated that India will emerge as the second largest manufacturing hub in 2012, overtaking Italy. The Indian pharmaceutical industry has been growing steadily at 14% for the last 3 years. What has been noteworthy is the rapid upgradation in the standards and quality of manufacturing. Indeed, one of the primary reasons why more and more manufacturers are shifting to India is due to this rapid scale up in plant, machinery and processes that match international standards. Another area where the Indian pharmaceutical industry has made significant advances has been in R&D. R&D forms a critical part of this industry as new products and new processes lend a substantial advantage. At Anuh Pharma Limited, we have acquired assets of a Spanish R&D laboratory. The acquisition of the R&D laboratory will further add to the strengths of the company as well as to the overall strength of the Group. As we move forward, we are confident that Anuh Pharma Limited will continue MI to play a dominant role in the Indian pharmaceutical and API space and keep building on the momentum and deliver yet better results. Yours faithfully, Jayantilal P. Shah Chairman

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard